NorthStar FDA Monday, August 3, 1998 0.00 Neutral

FDA Approves LABETALOL HYDROCHLORIDE — NorthStar Rx LLC

# FDA Approves NorthStar Rx LLC's Labetalol Hydrochloride for Oral Administration NorthStar Rx LLC has received FDA approval for its generic labetalol hydrochloride oral formulation, expanding the competitive landscape in the antihypertensive market and potentially increasing price pressure on branded alternatives. The approval of this combined alpha and beta-blocker generic could enhance market accessibility and affordability for hypertension patients while providing NorthStar with an established revenue stream in the cardiovascular therapeutics sector.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day